EPS for ABIOMED, Inc. (ABMD) Expected At $0.64

April 17, 2018 - By Peter Erickson

ABIOMED, Inc. (NASDAQ:ABMD) LogoInvestors sentiment decreased to 1.18 in Q4 2017. Its down 0.12, from 1.3 in 2017Q3. It turned negative, as 19 investors sold ABIOMED, Inc. shares while 110 reduced holdings. 55 funds opened positions while 97 raised stakes. 36.44 million shares or 5.39% less from 38.51 million shares in 2017Q3 were reported.
Citadel Advsrs Ltd Liability Corporation stated it has 13,164 shares or 0% of all its holdings. M&T Commercial Bank holds 1,184 shares or 0% of its portfolio. Dimensional Fund Advisors Ltd Partnership holds 0.01% or 135,868 shares in its portfolio. Cwm Limited Liability Co reported 0% of its portfolio in ABIOMED, Inc. (NASDAQ:ABMD). Fifth Third State Bank reported 5 shares. D E Shaw & Incorporated owns 71,531 shares for 0.02% of their portfolio. Perceptive Advsrs Lc invested in 215,000 shares. Quantitative Mgmt Ltd Liability reported 14,700 shares. X Management Limited Liability Corp accumulated 452 shares. Glenmede Tru Na holds 0% or 2,781 shares. Renaissance Techs Llc stated it has 1.08 million shares or 0.22% of all its holdings. Advsrs Asset Mgmt invested in 0.06% or 18,297 shares. Ubs Asset Mgmt Americas Inc holds 0.02% or 106,597 shares. Quantbot Technologies L P has invested 0.08% in ABIOMED, Inc. (NASDAQ:ABMD). Citigroup holds 32,243 shares.

Since February 20, 2018, it had 0 insider purchases, and 1 insider sale for $5.41 million activity.

Analysts expect ABIOMED, Inc. (NASDAQ:ABMD) to report $0.64 EPS on May, 3.They anticipate $0.31 EPS change or 93.94 % from last quarter’s $0.33 EPS. ABMD’s profit would be $28.34 million giving it 118.92 P/E if the $0.64 EPS is correct. After having $0.70 EPS previously, ABIOMED, Inc.’s analysts see -8.57 % EPS growth. The stock increased 2.74% or $8.11 during the last trading session, reaching $304.43. About 509,593 shares traded or 16.13% up from the average. ABIOMED, Inc. (NASDAQ:ABMD) has risen 128.67% since April 18, 2017 and is uptrending. It has outperformed by 117.12% the S&P500.

ABIOMED, Inc. (NASDAQ:ABMD) Ratings Coverage

Among 8 analysts covering Abiomed (NASDAQ:ABMD), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Abiomed had 12 analyst reports since November 2, 2017 according to SRatingsIntel. The company was maintained on Thursday, November 2 by Jefferies. The firm has “Buy” rating by Piper Jaffray given on Thursday, January 4. As per Friday, February 2, the company rating was maintained by Guggenheim. The firm has “Equal-Weight” rating given on Friday, February 2 by Morgan Stanley. The rating was maintained by Jefferies with “Buy” on Thursday, December 21. Piper Jaffray maintained ABIOMED, Inc. (NASDAQ:ABMD) on Thursday, February 1 with “Buy” rating. Stephens maintained ABIOMED, Inc. (NASDAQ:ABMD) rating on Monday, April 9. Stephens has “Buy” rating and $30000 target. The firm has “Buy” rating given on Thursday, February 1 by Jefferies. On Friday, February 16 the stock rating was maintained by SunTrust with “Buy”. The company was maintained on Friday, February 2 by Stephens.

ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. The company has market cap of $13.48 billion. It also provides continuum of care to heart failure patients. It has a 152.75 P/E ratio. The firm offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter axial flow pump.

ABIOMED, Inc. (NASDAQ:ABMD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.